Antinociceptive and antidepressive efficacies of the combined ineffective doses of S-ketamine and URB597
- 94 Downloads
Clinical studies have demonstrated that the NMDA receptor antagonist ketamine produces rapid antidepressant responses. There are safety concerns and adverse effects that limit the utilization of ketamine in psychiatry. Some studies have suggested combination therapy for optimal ketamine use. In this study, we evaluated the potential for combination therapy of ineffective doses of ketamine and fatty acid amide hydrolase inhibitor URB597 for the treatment of depression and pain in male NMRI mice. Intraperitoneal administration of ketamine (10 mg/kg) at the time intervals of 115, 145, and 160 min and ketamine (5 mg/kg) at the time interval of 160 min after administration increased the tail-flick latency, indicating an antinociceptive effect. The same doses of ketamine decreased immobility time in the forced swim test (FST), showing an antidepressant-like effect. Moreover, URB597 at the doses of 0.5 and 1 mg/kg induced an antinociceptive effect, while it at the dose of 1 mg/kg produced an antidepressant-like response. Furthermore, co-administration of the ineffective doses of ketamine (2.5 mg/kg) and URB597 (0.1 mg/kg) caused antinociceptive and antidepressant-like effects, while each one of them alone did not alter the performance of mice in the FST and tail-flick tests. It should be noted that none of the treatments alter animal locomotor activity compared to the control group. Therefore, the combined administration of ineffective doses of ketamine and URB597 might be an effective strategy in the therapy of depression and pain.
KeywordsAntinociceptive Antidepressant-like effect S-ketamine URB597 Mice
FS acquired the animal data. ME wrote the manuscript. ME, FK, and MZ were responsible for the study concept, design, and assisted with the data analysis and interpretation of findings. All authors critically reviewed the content and approved the final version for publication.
Compliance with ethical standards
The study was carried out in accordance with ethical standards in all aspects.
Conflict of interest
The authors declare that they have no conflict of interest.
- Bortolato M, Mangieri RA, Fu J, Kim JH, Arguello O, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D (2007) Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress. Biol Psychiatry 62:1103–1110. https://doi.org/10.1016/j.biopsych.2006.12.001 CrossRefPubMedGoogle Scholar
- D’Amour FE, Smith DL (1941) A method for determining loss of pain sensation. J Pharmacol Exp Ther 72:74–79Google Scholar
- Garcia LSB, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J (2008) Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuro-Psychopharmacol Biol Psychiatry 32:140–144. https://doi.org/10.1016/j.pnpbp.2007.07.027 CrossRefGoogle Scholar
- Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Cassano T, Morgese MG, Debonnel G, Duranti A, Tontini A, Tarzia G, Mor M, Trezza V, Goldberg SR, Cuomo V, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102:18620–18625. https://doi.org/10.1073/pnas.0509591102 CrossRefPubMedPubMedCentralGoogle Scholar
- Hampson AJ, Bornheim LM, Scanziani M, Yost CS, Gray AT, Hansen BM, Leonoudakis DJ, Bickler PE (2002) Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 70:671–676. https://doi.org/10.1046/j.1471-4159.1998.70020671.x CrossRefGoogle Scholar
- Jagtap A, Bhaskar M (2013) Evaluation of antidepressant and antinociceptive activity of escitalopram. Indian J Pharm Educ Res 47:97–102Google Scholar
- Jiang H, Gong D, Zhou C (2018) Inhibition of fatty acid amide hydrolase improves depressive-like behaviors independent of its peripheral antinociceptive effects in a rat model of neuropathic pain. XXX:1–11. https://doi.org/10.1213/ANE.0000000000003563
- Liu Q, Bhat M, Bowen WD, Cheng J (2009) Signaling pathways from cannabinoid receptor-1 activation to inhibition of n-methyl- d -aspartic acid mediated calcium influx and neurotoxicity in dorsal root ganglion. Neurons 331:1062–1070. https://doi.org/10.1124/jpet.109.156216.Cannabinoid CrossRefGoogle Scholar
- Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, Putman D (2006) Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12:21–38. https://doi.org/10.1111/j.1527-3458.2006.00021.x CrossRefPubMedPubMedCentralGoogle Scholar
- Russo R, Loverme J, La Rana G et al (2007) The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther 322:236–242. https://doi.org/10.1124/jpet.107.119941 CrossRefPubMedGoogle Scholar
- Sanchez-Blazquez P, Rodriguez-Munoz M, Vicente-Sanchez A, Garzon J (2013) Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate. Antioxid Redox Signal 19:1766–1782. https://doi.org/10.1089/ars.2012.5100 CrossRefPubMedPubMedCentralGoogle Scholar
- Sanchez-Blazquez P, Rodriguez-Munoz M, Herrero-Labrador R et al (2014) The calcium-sensitive Sigma-1 receptor prevents cannabinoids from provoking glutamate NMDA receptor hypofunction: implications in antinociception and psychotic diseases. Int J Neuropsychopharmacol 17:1943–1955. https://doi.org/10.1017/S1461145714000029 CrossRefPubMedGoogle Scholar
- Wang J, Goffer Y, Xu D, Tukey DS, Shamir DB, Eberle SE, Zou AH, Blanck TJJ, Ziff EB (2011) A single subanesthetic dose of ketamine relieves depression-like behaviors induced by neuropathic pain in rats. Anesthesiology 115:812–821. https://doi.org/10.1097/ALN.0b013e31822f16ae CrossRefPubMedPubMedCentralGoogle Scholar
- Zhuang S-Y, Bridges D, Grigorenko E, McCloud S, Boon A, Hampson RE, Deadwyler SA (2005) Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology 48:1086–1096. https://doi.org/10.1016/j.neuropharm.2005.01.005 CrossRefPubMedGoogle Scholar